Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of lymphoma associated with a poor prognosis. Chemotherapy is the mainstay of frontline treatment for patients with this disease. Despite high response rates to combination chemotherapy regimens, the majority of patients relapse within a few years of treatment. Therefore, finding efficacious treatments for relapsed or refractory disease has become a growing area of clinical research. The mammalian target of rapamycin (mTOR) is responsible for integrating cell signals from growth factors, hormones, and nutrients and communicating energy status. Scientific research on aberrant molecular pathways in cancer has revealed that several proteins along the mTOR pathway may be upregulated in this and other types of lymphoma. Temsirolimus is the first mTOR inhibitor that has shown clinical efficacy in treating MCL that has relapsed after frontline treatments

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal outcome. Current clinical parameters do not allow accurate risk stratification, and personalized therapies are lacking. In fact, Hodgkin lymphoma (HL) is often over- or undertreated because of this lack of accurate risk stratification. In recent years, the early detection of chemoresistance by fluorodeoxyglucose positron emission tomography has become the most important prognostic tool in the management of HL. However, to date, no prognostic scores or molecular markers are available for the early identification of patients at very high risk of failure of induction therapy. In the last decade, many important advances have been made in understanding the biology of HL. In particular, the development of new molecular profiling technologies, such as SNP arrays, comparative genomic hybridization, and gene-expression profiling, have allowed the identification of new prognostic factors that may be useful for risk stratification and predicting response to chemotherapy. In this review, we focus on the prognostic tools and biomarkers that are available for newly diagnosed HL, and we highlight recent advances in the genomic characterization of classical HL and potential targets for therapy

Les déterminants de l’intégration sur le marché d’emploi des personnes migrantes et réfugiées au Maroc : Cas du projet AMUDDU

The aim of this paper is to reveal the determinants involved in the professional integration of migrants and refugees in Morocco. To achieve this, we used a database collected by ENABEL and AMAPPE, from a questionnaire administered in 2019 and 2022. This survey identified 697 hosted and informed migrants and refugees. Its objective was to ask migrants and refugees who are beneficiaries of the AMUDDU project about their employment status. We use a logistic regression model to identify the probability that a migrant is inserted. The dependent variable in our analysis is the job insertion which takes two variables (1 if inserted and 0 otherwise). The independent (predictive) variables are: Age, length of stay, gender, language level, degree, work experience, scholarship and number of children. Our logistic regression results show that the probability of entering the labor market is determined by the length of stay in Morocco, the level of proficiency in Arabic and French, professional experience and degree. However, age, gender, scholarship, and number of children do not seem to have a significant influence on labor market integration.  Despite the relevance of the results obtained. This is a first step in the analysis of the explanatory determinants of the problem of professional integration in Morocco. Thus, an impact study based on the counterfactual situation can represent a logical continuation of our wok.     JEL Classification: O15, J61 Paper type: Empirical researchL’objectif de cet article est de révéler les déterminants intervenant dans l’insertion professionnelle des migrants et des réfugiés au Maroc. Pour y parvenir, nous avons utilisé une base de données collectée par ENABEL et AMAPPE, issue d’un questionnaire administré en 2019 et en 2022. Cette enquête a identifié 697 migrants et réfugiés accueillis et informés. Son objectif était d’interroger les migrants et les réfugiés bénéficiaires du projet AMUDDU sur leur situation professionnelle. Nous utilisons un modèle de régression logistique pour identifier la probabilité qu'un migrant soit inséré. La variable dépendante dans notre analyse est l’insertion professionnelle qui prend deux variables (1 si inséré et 0 sinon). Les variables indépendantes (prédictives) sont : L’âge, la durée de séjour, le genre, le niveau linguistique, le diplôme, l’expérience professionnelle, la bourse et le nombre d’enfants. Nos résultats de régression logistique montrent que la probabilité de s'insérer sur le marché du travail est déterminée par la durée de séjour passée sur le territoire marocain, le niveau de maitrise de la langue arabe et de la langue française, l’expérience professionnelle et le diplôme. Cependant, l’âge, le genre, la bourse et le nombre d’enfants ne semblent pas avoir une influence significative sur l’insertion sur le marché d’emploi. Malgré la pertinence des résultats obtenus. Il s'agit d'une première étape dans l'analyse des déterminants explicatifs de la problématique d'insertion professionnelle au Maroc. Ainsi, une étude d’impact en se basant sur la situation contrefactuelle peut représenter une suite logique de notre travail.     Classification JEL : O15, J61 Type de l’article : Recherche appliqué

Unveiling the Influence of User-Generated Content on Tourist Destination Choice: Insights from Moroccan Travel Experiences

This study explores the impact of User-Generated Content (UGC) on local tourists' decision- making when choosing Morocco as their travel destination. It examines factors such as perceived value, enjoyment, risks, and privacy concerns. The research involves in-depth interviews with 10 tourists who have visited Morocco. The study examines how tourists use UGC to plan their trips, their perceptions of information on social media and online review sites, and the broader impacts of UGC on their travel experiences. The findings offer valuable insights into the role of UGC in shaping destination choices and offer practical implications for improving the overall tourist experience in Morocco's tourism industry

Primary Malignant Melanoma of the Gastric Antrum: A Case Report

Primary melanoma of the antrum is a rare and aggressive disease. Diagnosis requires a correlation between the patient's history, tumor histopathology, and immunohistochemistry. Surgery and mutation‐targeted treatments may improve overall survival

An Unusual Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma on Mammography: Case Report

Although rare, breast CLL/SLL should be considered in the differential diagnosis of a breast mass. A high index of suspicion is needed to differentiate this neoplasm from more common breast carcinomas like solid variant of invasive lobular carcinoma

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. Three separate cohorts of patients (with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) received buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent. The primary endpoint was overall response rate based on a 6-month best overall response by cohort; secondary endpoints included progression-free survival, duration of response, overall survival, safety, and tolerability. Overall, 72 patients (26 with diffuse large B-cell lymphoma, 22 with mantle cell lymphoma, and 24 with follicular lymphoma) were treated. The overall response rates were 11.5%, 22.7%, and 25.0% in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, respectively; two patients (one each with diffuse large B-cell lymphoma and mantle cell lymphoma) achieved a complete response. The most frequently reported (>20%) adverse events of any grade in the population in which safety was studied were hyperglycemia, fatigue, and nausea (36.1% each), depression (29.2%), diarrhea (27.8%), and anxiety (25.0%). The most common grade 3/4 adverse events included hyperglycemia (11.1%) and neutropenia (5.6%). Buparlisib showed activity in relapsed or refractory non-Hodgkin lymphoma, with disease stabilization and sustained tumor burden reduction in some patients, and acceptable toxicity. Development of mechanism-based combination regimens with buparlisib is warranted

Histone deacetylase inhibitors in Hodgkin lymphoma

Although Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging. Furthermore, because of the young age of these patients, the impact of early mortality on the number of years lost from productive life is remarkable. Patients with relapsed HL post stem cell transplantation currently have no curative therapy, and are in need for new drugs and novel treatment strategies. While no new drugs have been approved for the treatment of patients with HL in more than three decades, several new agents are demonstrating promising results in early clinical trials. This review will focus on the emerging role of histone deacetylase inhibitors in patients with relapsed HL

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). In DLBCL, PD-L1 elevation was more frequent in responders versus nonresponders (5/8 [62.5%] vs. 3/16 [18.8%]; p = 0.065; complete response 37.5% vs. 0%; p = 0.028). Overall response rates for patients with WES and GEP data, respectively, were: DLBCL (38.5% and 29.6%); FL (46.2% and 43.5%); RT (76.5% and 81.3%). In DLBCL, WES analyses demonstrated that mutations in RNF213 (40.0% vs. 6.2%; p = 0.055), KLHL14 (30.0% vs. 0%; p = 0.046), and LRP1B (30.0% vs. 6.2%; p = 0.264) were more frequent in responders. No responders had mutations in EBF1, ADAMTS20, AKAP9, TP53, MYD88, or TNFRSF14, while the frequency of these mutations in nonresponders ranged from 12.5% to 18.8%. In FL and RT, genes with different mutation frequencies in responders versus nonresponders were: BCL2 (75.0% vs. 28.6%; p = 0.047) and ROS1 (0% vs. 50.0%; p = 0.044), respectively. Per GEP, the most upregulated genes in responders were LEF1 and BTLA (overall), and CRTAM (germinal center B-cell-like DLBCL). Enriched pathways were related to immune activation in responders and resistance-associated proliferation/replication in nonresponders. This preliminary work may help to generate hypotheses regarding genetically defined subsets of DLBCL, FL, and RT patients most likely to benefit from ibrutinib plus nivoluma